Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
New product launches and acquisitions lead to double-digit growth in sales, but higher spending caused profits to flatline.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 05:41:14.162397.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Roughly one out of every five adults suffers from sleep-disordered breathing. Left untreated, this condition can greatly increase a patient's chance of developing diabetes, heart disease, obesity, and more. Decades ago, ResMed (RMD 0.02%) pioneered a treatment called continuous positive airway pressure, or CPAP, which utilizes a pump and mask to keep a patient's airway open during the night. ResMed's sales and profits have consistently grown ever since. Coming into Monday night's earnings report, investors were expecting more of the same.
Let's take a closer look at the company's second-quarter performance to see how it fared during the period.
Image source: Getty Images.
|
Metric |
Q2 2017 |
Q2 2016 |
Change (YOY) |
|---|---|---|---|
|
Sales |
$530.4 million |
$454.5 million |
16.7% |
|
Net income |
$76.7 million |
$95.6 million |
(19.7%) |
|
Non-GAAP net income |
$103.3 million |
$102.5 million |
0.8% |
|
Non-GAAP EPS |
$0.73 |
$0.73 |
0% |
Looking beyond the numbers, ResMed also strengthened its product lineup during the quarter. The company announced FDA approval of the AirMini, which is a tiny CPAP machine designed to be used while traveling. The company also launched two new masks during the quarter -- AirFit F20 and AirFit N20 -- which utilize the company's new sealing technology. Demand for these new masks is outpacing supply, so the company is working hard to ramp up production.
CEO Mick Farrell expressed his enthusiasm for the company's quarterly performance and new product offerings:
We continue to pioneer game-changing products and create value with our solutions. This quarter we announced: FDA clearance for the world's smallest travel CPAP; the creation of SleepScore Labs to focus on consumer sleep wellness; reaching the milestone of one billion nights of sleep data; and new research demonstrating that the use of myAir significantly improves patient adherence to sleep therapy in Europe.
He also reminded investors that the company remains well positioned to deliver on its longer-term goals, noting:
We are focused on our goal of changing the lives of 20 million patients by 2020, and we continue to lead the industry through an exciting pipeline of new products and connected care solutions that improve patient outcomes, create efficiencies for our homecare customers, and help physicians and providers better manage chronic disease and lower healthcare costs.
ResMed's headline numbers compared favorably to Wall Street's expectations. In response, shares rose by almost 10% on Tuesday. Given the strong demand for the company's new products and management's laser-like focus on increasing awareness of sleep disorders, ResMed continues to look well positioned to deliver sales and earnings gains from here.